Combimist-L CFC Free Inhaler

Combimist-L CFC Free Inhaler is a metered dose inhaler with Salbutamol sulphate and Ipratropium Bromide as an active ingredient they are short-acting beta-2 adrenergic agonist (SABA) and an anticholinergic bronchodilator. This combination of Salbutamol and Ipratropium is with dual action bronchospasm in asthma, COPD and other Obstructive airway disease.

Key Features

How does Combimist-L CFC Free Inhaler work?

• Salbutamol sulphate may selectively stimulate beta-2 adrenergic receptors in bronchial smooth muscle.
• It may also activates adenylate cyclic AMP that reduces intracellular calcium that may causes muscle relaxation.

Usage

• In the condition of Bronchospasm associated with asthma and Chronic Obstructive Pulmonary Disorder (COPD) i.e., Chronic Bronchitis and Emphysema.
• Reversible Airway Obstruction.

Dosage

• Usual Dose: 2 puffs (200 mcg salbutamol + 40 mcg ipratropium) every 6–8 hours as needed.
• Maximum Daily Dose: 12 puffs (1200 mcg salbutamol + 240 mcg ipratropium) per day.
• Shake inhaler well before use. Exhale fully, place mouthpiece in mouth, seal lips tightly.
• Actuate device during slow, deep inhalation. Hold breath for 10 seconds, then exhale slowly.

Side Effects

• Dry mouth
• Headache
• Tremor
• Nervousness / anxiety
• Throat irritation
• Cough
• Palpitations / tachycardia
• Nausea
• Muscle cramps
• Dizziness
• Blurred vision (due to ipratropium)
• Urinary retention (rare, especially in elderly males)

Drug Interactions

• Beta-blockers (especially non-selective like propranolol): Antagonize effect and may cause severe bronchospasm.
• Other sympathomimetics (e.g., ephedrine, pseudoephedrine): Additive cardiovascular effects and increased risk of tachycardia, hypertension.
• Diuretics: May potentiate hypokalemia.
• Monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants: May enhance cardiovascular effects.
• Digoxin: Increased risk of arrhythmias due to hypokalemia.

Pharmacokinetics

• Absorption of salbutamol is minimal systemic absorption via inhalation (approx. 10–20%) and of Ipratropium is less than 10%.
• Onset of salbutamol is 5–15 minutes and Ipratropium is 15-30 minutes.
• Reaches the Peak plasma (salbutamol) in 60–90 minutes and in the condition of Ipratropium reaches peak plasma in 1-2 hours.
• The half-life of salbutamol is 3–6 hours and ipratropium can be 2 hours.
• Metabolism: Hepatic; excreted in urine as metabolites and unchanged drug.

Precautions

• The one with medical history i.e., cardiovascular disorders (arrhythmias, hypertension), hyperthyroidism, diabetes mellitus, or seizure disorders should avoid taking such medications.
• Monitor serum theophylline levels periodically, especially during initiation or dose adjustment as it may vary from individual need and tolerance and also monitor side effects.
• In the condition of Pregnancy or breast feeding should avoid using such medications.
• The age group below 12 should avoid taking any such medications.

Conclusion

Combimist-L CFC-Free Inhaler is a clinically effective, dual-action bronchodilator combining salbutamol and ipratropium for rapid relief of bronchospasm in asthma and COPD. It is also free of CFCs, safe for the environment and effective in terms of reliability. While generally well-tolerated, caution is advised regarding potential cardiovascular and anticholinergic side effects. It should be used as rescue medication and not as substitute for controller therapy (e.g., inhaled corticosteroids). Always consult a healthcare professional before initiating or adjusting therapy.

FAQ’S